Manufactured by Novo Nordisk
First of its kind: Wegovy Pill (oral semaglutide 25mg) was FDA-approved December 22, 2025 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, and to reduce major adverse cardiovascular events. Approval was based on the Phase 3 OASIS 4 trial, which showed a mean 16.6% body weight reduction among adherent participants. Launched in the US in early January 2026. Same active ingredient as Wegovy injection, but taken once daily by mouth on an empty stomach.
FDA-approved oral semaglutide for chronic weight management. Once-daily 25mg tablet (with 1.5/4/9mg titration steps). $149/mo via NovoCare Pharmacy self-pay.
See Wegovy Pill savings and coverage →FDA Status
FDA Approved
Route
oral
Approved Indications
Typical Dose Range
1.5mg → 4mg → 9mg → 25mg daily (16-week titration; 25mg maintenance)
Dosing is determined by your prescribing provider based on your individual needs. Most GLP-1 medications follow a gradual titration schedule, starting at a low dose and increasing over several weeks to reduce side effects.
Branded (Retail)
$1,300/mo
Savings Program
$149/mo
Prices are estimates and may vary by pharmacy, location, and insurance coverage. Contact your provider for accurate pricing.
This is not a complete list of side effects. Talk to your healthcare provider about what to expect and when to seek medical attention.
This site is for educational purposes only and is not medical advice. Always consult a healthcare provider before starting any medication. Full disclaimer
Wegovy is the FDA-approved semaglutide brand for weight loss, available as both a weekly pen and a once-daily pill. See our full pillar covering every coupon, cost breakdown, and access path.
